Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 3.02 USD 1% Market Closed
Market Cap: 271.6m USD
Have any thoughts about
Chimerix Inc?
Write Note

Chimerix Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chimerix Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Chimerix Inc
NASDAQ:CMRX
Total Current Assets
$140.9m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
-3%
Abbvie Inc
NYSE:ABBV
Total Current Assets
$27.8B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
5%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Assets
$13.1B
CAGR 3-Years
-2%
CAGR 5-Years
-14%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Total Current Assets
$26.8B
CAGR 3-Years
3%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Assets
$9.8B
CAGR 3-Years
3%
CAGR 5-Years
15%
CAGR 10-Years
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Assets
$19.3B
CAGR 3-Years
12%
CAGR 5-Years
22%
CAGR 10-Years
24%
No Stocks Found

Chimerix Inc
Glance View

Market Cap
271.6m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
2.98 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Chimerix Inc's Total Current Assets?
Total Current Assets
140.9m USD

Based on the financial report for Sep 30, 2024, Chimerix Inc's Total Current Assets amounts to 140.9m USD.

What is Chimerix Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-3%

Over the last year, the Total Current Assets growth was -30%. The average annual Total Current Assets growth rates for Chimerix Inc have been 3% over the past three years , 2% over the past five years , and -3% over the past ten years .

Back to Top